Edward M. Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Edward M. Brown has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Steven C. Hebert
Dept. of Med. Emory U. Med. Sch., Atlanta
8 shared publications - Naibedya Chattopadhyay
Division of Endocrinology and Centre for Research in ASTHI, CSIR-Central Drug Research Institute, Council of Scientific and Industrial Research, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
4 shared publications O Kifor
3 shared publicationsP M Vassilev
3 shared publications- Daniela Riccardi
School of Biological Sciences, Oxford Road, Manchester M13 9PT, UK
2 shared publications A A Kato
Depts of Med., Harvard Med. Sch., Boston
1 shared publication
Latest Publications
- 12 March 2003
- Published by Springer Nature in Osteoporosis International
- Vol. 14 (S3) , 25-34
Is the calcium receptor a molecular target for the actions of strontium on bone?
The extracellular calcium-sensing receptor (CaR) plays key roles in maintaining extracellular calcium homeostasis by enabling several of the cells and tissues involved in this process to sense small changes in Ca2+o and to respond with changes in cellular function that will restore Ca2+o to its normal level. The chief cells of the parathyroid gland and the thyroidal C-cells, for example, respond to decreases in Ca2+o with increased secretion of the Ca2+o-elevating hormone, parathyroid hormone (PTH), and decreased secretion of the Ca2+o-lowering hormone, calcitonin, respectively. The cells of the renal distal tubule are likewise capable of sensing Ca2+o and respond to decreases in Ca2+o with increased tubular reabsorption of Ca2+ and vice versa, alterations in tubular function that will contribute to normalization of Ca2+o. The skeleton also plays key roles in maintaining Ca2+o homeostasis and both osteoblasts and osteoclasts can sense Ca2+o, with elevations in Ca2+o promoting bone formation and inhibiting bone resorption. It has been suggested that Sr2+ could act on bone via the CaR; however, the molecular mechanisms through which Ca2+o and Sr2+o exert these actions on bone cells remain controversial. Therefore, identifying their molecular target(s) would have significant implications for the treatment of bone loss. Ideally, therapies should simultaneously inhibit bone resorption while stimulating bone formation. Administration of strontium produces exactly those effects. Previous studies with dispersed bovine parathyroid cells as well as a preliminary study using CaR-transfected Chinese hamster ovary (CHO) cells indicate that Sr2+o is an agonist of the CaR, albeit with slightly lower efficacies and potencies than Ca2+o. Given that Sr2+o is distributed preferentially in bone, therefore, an action of this divalent cation on the CaR in bone cells represents one possible mechanism by which strontium ranelate, a new antiosteoporotic drug, exerts it skeletal actions in vivo.
- 12 March 2003
- Published by Springer Nature in Osteoporosis International
- Vol. 14 (S3) , 25-34
Is the calcium receptor a molecular target for the actions of strontium on bone?
The extracellular calcium-sensing receptor (CaR) plays key roles in maintaining extracellular calcium homeostasis by enabling several of the cells and tissues involved in this process to sense small changes in Ca2+o and to respond with changes in cellular function that will restore Ca2+o to its normal level. The chief cells of the parathyroid gland and the thyroidal C-cells, for example, respond to decreases in Ca2+o with increased secretion of the Ca2+o-elevating hormone, parathyroid hormone (PTH), and decreased secretion of the Ca2+o-lowering hormone, calcitonin, respectively. The cells of the renal distal tubule are likewise capable of sensing Ca2+o and respond to decreases in Ca2+o with increased tubular reabsorption of Ca2+ and vice versa, alterations in tubular function that will contribute to normalization of Ca2+o. The skeleton also plays key roles in maintaining Ca2+o homeostasis and both osteoblasts and osteoclasts can sense Ca2+o, with elevations in Ca2+o promoting bone formation and inhibiting bone resorption. It has been suggested that Sr2+ could act on bone via the CaR; however, the molecular mechanisms through which Ca2+o and Sr2+o exert these actions on bone cells remain controversial. Therefore, identifying their molecular target(s) would have significant implications for the treatment of bone loss. Ideally, therapies should simultaneously inhibit bone resorption while stimulating bone formation. Administration of strontium produces exactly those effects. Previous studies with dispersed bovine parathyroid cells as well as a preliminary study using CaR-transfected Chinese hamster ovary (CHO) cells indicate that Sr2+o is an agonist of the CaR, albeit with slightly lower efficacies and potencies than Ca2+o. Given that Sr2+o is distributed preferentially in bone, therefore, an action of this divalent cation on the CaR in bone cells represents one possible mechanism by which strontium ranelate, a new antiosteoporotic drug, exerts it skeletal actions in vivo.
- 1 December 1998
- Vol. 24 (4) , 449-58
Extracellular calcium-sensing receptor in rat oligodendrocytes: expression and potential role in regulation of cellular proliferation and an outward K+ channel.
A G protein-coupled, extracellular calcium (Ca(0)2+)-sensing receptor (CaR) cloned from parathyroid, kidney, and brain plays crucial roles in systemic calcium metabolism. In brain, the CaR is located in nerve terminals as well as in fiber tracts, where it may be expressed in glia. Moreover, there is Ca2+- and K+-dependent communication between axons and oligodendroglia. To investigate further the potential role of the CaR in oligodendroglia, we studied expression of CaR mRNA and protein as well as the effects of CaR agonists on cellular proliferation and Ca2+-activated K+ channel activity in immature rat oligodendrocytes in primary culture. Reverse transcriptase polymerase chain reaction and sequencing of CaR transcripts from oligodendrocytes revealed >99% sequence identity with the rat kidney CaR. Northern analysis demonstrated 7.5 and 4.1 kb transcripts in oligodendrocytes, similar to those in rat parathyroid and kidney, while Western analysis and immunocytochemistry with CaR-specific antisera showed the presence of CaR protein. Immunocytochemically, the CaR was colocalized with galactocerebroside in the cultured oligodendrocytes. Raising Ca(0)2+ from 1.8 to 4.8 mM or addition of the polycationic CaR agonist neomycin (300 microM) modestly but significantly increased [3H]-thymidine incorporation into oligodendrocytes. Elevating Ca(0)2+ from 0.75 to 3.0 mM or addition of 100 microM neomycin also produced 2-2.5-fold increases in the open state probability (Po) of an outward K+ channel with a unitary conductance of 88+/-5 pS. Taken together, our data show that the CaR is expressed in immature oligodendrocytes and may be functionally linked to cellular proliferation and an outward K+ channel potentially contributing to local ionic homeostasis in the vicinity of oligodendroglia.
- 1 December 1998
- Vol. 24 (4) , 449-58
Extracellular calcium-sensing receptor in rat oligodendrocytes: expression and potential role in regulation of cellular proliferation and an outward K+ channel.
A G protein-coupled, extracellular calcium (Ca(0)2+)-sensing receptor (CaR) cloned from parathyroid, kidney, and brain plays crucial roles in systemic calcium metabolism. In brain, the CaR is located in nerve terminals as well as in fiber tracts, where it may be expressed in glia. Moreover, there is Ca2+- and K+-dependent communication between axons and oligodendroglia. To investigate further the potential role of the CaR in oligodendroglia, we studied expression of CaR mRNA and protein as well as the effects of CaR agonists on cellular proliferation and Ca2+-activated K+ channel activity in immature rat oligodendrocytes in primary culture. Reverse transcriptase polymerase chain reaction and sequencing of CaR transcripts from oligodendrocytes revealed >99% sequence identity with the rat kidney CaR. Northern analysis demonstrated 7.5 and 4.1 kb transcripts in oligodendrocytes, similar to those in rat parathyroid and kidney, while Western analysis and immunocytochemistry with CaR-specific antisera showed the presence of CaR protein. Immunocytochemically, the CaR was colocalized with galactocerebroside in the cultured oligodendrocytes. Raising Ca(0)2+ from 1.8 to 4.8 mM or addition of the polycationic CaR agonist neomycin (300 microM) modestly but significantly increased [3H]-thymidine incorporation into oligodendrocytes. Elevating Ca(0)2+ from 0.75 to 3.0 mM or addition of 100 microM neomycin also produced 2-2.5-fold increases in the open state probability (Po) of an outward K+ channel with a unitary conductance of 88+/-5 pS. Taken together, our data show that the CaR is expressed in immature oligodendrocytes and may be functionally linked to cellular proliferation and an outward K+ channel potentially contributing to local ionic homeostasis in the vicinity of oligodendroglia.
- 1 February 1998
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 49 (1) , 15-29
The Extracellular Calcium-Sensing Receptor: Its Role in Health and Disease
The recent cloning of an extracellular calcium (Ca2+o)-sensing receptor (CaR) from parathyroid, kidney and other cell types has clarified the mechanisms through which Ca2+oexerts its direct actions on various cells and tissues. In the parathyroid, the CaR mediates the inhibitory effects of Ca2+oon parathyroid hormone (PTH) secretion and likely on expression of the PTH gene and parathyroid cellular proliferation. In the kidney, the receptor mediates direct inhibition of the reabsorption of divalent cations in the cortical thick ascending limb, and it likely underlies the inhibitory actions of hypercalcemia on the urinary-concentrating mechanism in the medullary thick ascending limb and inner medullary collecting duct. The identification of inherited diseases of Ca2+o-sensing that arise from mutations in the CaR gene has proven, by genetic means, the central role of the CaR in mineral ion homeostasis and the importance of the receptor in regulating the parathyroid and kidney. An allosteric CaR agonist (“calcimimetic”) is currently being tested for the treatment of primary hyperparathyroidism, and CaR-based therapeutics will likely be applicable to other disorders in which CaRs are under- or overactive. Thus the discovery of the CaR and its associated diseases has documented that Ca2+oplays an essential role as an extracellular first messenger, in addition to serving its better recognized role as an intracellular second messenger.
- 1 February 1998
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 49 (1) , 15-29
The Extracellular Calcium-Sensing Receptor: Its Role in Health and Disease
The recent cloning of an extracellular calcium (Ca2+o)-sensing receptor (CaR) from parathyroid, kidney and other cell types has clarified the mechanisms through which Ca2+oexerts its direct actions on various cells and tissues. In the parathyroid, the CaR mediates the inhibitory effects of Ca2+oon parathyroid hormone (PTH) secretion and likely on expression of the PTH gene and parathyroid cellular proliferation. In the kidney, the receptor mediates direct inhibition of the reabsorption of divalent cations in the cortical thick ascending limb, and it likely underlies the inhibitory actions of hypercalcemia on the urinary-concentrating mechanism in the medullary thick ascending limb and inner medullary collecting duct. The identification of inherited diseases of Ca2+o-sensing that arise from mutations in the CaR gene has proven, by genetic means, the central role of the CaR in mineral ion homeostasis and the importance of the receptor in regulating the parathyroid and kidney. An allosteric CaR agonist (“calcimimetic”) is currently being tested for the treatment of primary hyperparathyroidism, and CaR-based therapeutics will likely be applicable to other disorders in which CaRs are under- or overactive. Thus the discovery of the CaR and its associated diseases has documented that Ca2+oplays an essential role as an extracellular first messenger, in addition to serving its better recognized role as an intracellular second messenger.
- 1 January 1998
- Vol. 53, 257
The calcium-sensing receptor (CaR) permits Ca2+ to function as a versatile extracellular first messenger.
The ability of parathyroid cells to recognize and respond to (i.e., "sense") small changes in the extracellular Ca2+ concentration (Ca2+o) plays a crucial role in mineral ion homeostasis. Expression cloning in Xenopus laevis oocytes enabled isolation of a cDNA coding for the bovine parathyroid CaR. CaRs were later isolated from human parathyroid and kidney, rat kidney, brain and C-cell, rabbit kidney, and chicken parathyroid. All are tissue and species homologs of the same ancestral gene. The predicted CaR protein has a large extracellular amino-terminus, which binds polycationic CaR agonists; a central core with seven membrane-spanning helices, documenting that it is a G protein-coupled receptor; and an approximately 200 amino acid carboxyl-terminal tail. The CaR is highly expressed in parathyroid and C-cells, along almost the entire nephron and gastrointestinal (GI) tract and within numerous regions of the brain, particularly hippocampus, cerebellum, and hypothalamus. The CaR's physiological importance has been documented by the identification of hyper- and hypocalcemic syndromes due to inactivating or activating CaR mutations, respectively. Familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT) are caused by loss-of-function CaR mutations producing Ca2+o "resistance," while autosomal dominant hypocalcemia is the result of activating mutations rendering CaRs overly sensitive to Ca2+o. In addition to showing altered parathyroid responsiveness to Ca2+o, patients with FHH reabsorb too much urinary Ca2+ and Mg2+ at a given Ca2+o, while those with autosomal dominant hypocalcemia excrete too much, illustrating the CaR's key role in renal handling of divalent cations. Recent in vitro data suggest that the CaR directly regulates renal water handling in the collecting duct. Indeed, patients with FHH concentrate their urine normally, despite their hypercalcemia, while those with autosomal dominant hypocalcemia can exhibit impaired urinary concentration at normal or even low Ca2+o, suggesting that the CaR enables coordination of renal calcium and water handling. In addition to serving these "homeostatic" roles, the CaR likely also enables Ca2+o to serve additional roles as an extracellular messenger. The receptor regulates key Ca2+ and K(+)-permeable ion channels in hippocampal and other brain cells and likely senses local changes in Ca2+o within the brain microenvironment accompanying neuronal activation. It is also present in and regulates ion channels in lens epithelial cells, potentially playing some role in cataract development in hypoparathyroid patients. In keratinocytes and epithelial cells of the gastrointestinal tract, in contrast, the CaR may regulate cellular proliferation and differentiation, processes known to be modulated by Ca2+o in these cell types. Thus, in addition to sensing and regulating systemic Ca2+o, the CaR likely enables Ca2+o to act as a local signal for cells within specific microenvironments, such as the brain or eye.
- 1 January 1998
- Vol. 53, 257
The calcium-sensing receptor (CaR) permits Ca2+ to function as a versatile extracellular first messenger.
The ability of parathyroid cells to recognize and respond to (i.e., "sense") small changes in the extracellular Ca2+ concentration (Ca2+o) plays a crucial role in mineral ion homeostasis. Expression cloning in Xenopus laevis oocytes enabled isolation of a cDNA coding for the bovine parathyroid CaR. CaRs were later isolated from human parathyroid and kidney, rat kidney, brain and C-cell, rabbit kidney, and chicken parathyroid. All are tissue and species homologs of the same ancestral gene. The predicted CaR protein has a large extracellular amino-terminus, which binds polycationic CaR agonists; a central core with seven membrane-spanning helices, documenting that it is a G protein-coupled receptor; and an approximately 200 amino acid carboxyl-terminal tail. The CaR is highly expressed in parathyroid and C-cells, along almost the entire nephron and gastrointestinal (GI) tract and within numerous regions of the brain, particularly hippocampus, cerebellum, and hypothalamus. The CaR's physiological importance has been documented by the identification of hyper- and hypocalcemic syndromes due to inactivating or activating CaR mutations, respectively. Familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT) are caused by loss-of-function CaR mutations producing Ca2+o "resistance," while autosomal dominant hypocalcemia is the result of activating mutations rendering CaRs overly sensitive to Ca2+o. In addition to showing altered parathyroid responsiveness to Ca2+o, patients with FHH reabsorb too much urinary Ca2+ and Mg2+ at a given Ca2+o, while those with autosomal dominant hypocalcemia excrete too much, illustrating the CaR's key role in renal handling of divalent cations. Recent in vitro data suggest that the CaR directly regulates renal water handling in the collecting duct. Indeed, patients with FHH concentrate their urine normally, despite their hypercalcemia, while those with autosomal dominant hypocalcemia can exhibit impaired urinary concentration at normal or even low Ca2+o, suggesting that the CaR enables coordination of renal calcium and water handling. In addition to serving these "homeostatic" roles, the CaR likely also enables Ca2+o to serve additional roles as an extracellular messenger. The receptor regulates key Ca2+ and K(+)-permeable ion channels in hippocampal and other brain cells and likely senses local changes in Ca2+o within the brain microenvironment accompanying neuronal activation. It is also present in and regulates ion channels in lens epithelial cells, potentially playing some role in cataract development in hypoparathyroid patients. In keratinocytes and epithelial cells of the gastrointestinal tract, in contrast, the CaR may regulate cellular proliferation and differentiation, processes known to be modulated by Ca2+o in these cell types. Thus, in addition to sensing and regulating systemic Ca2+o, the CaR likely enables Ca2+o to act as a local signal for cells within specific microenvironments, such as the brain or eye.
- 1 December 1997
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 12 (12) , 1959-1970
Expression of an Extracellular Calcium-Sensing Receptor in Human and Mouse Bone Marrow Cells
The cloning of a G protein–coupled, extracellular calcium (Ca2+e)-sensing receptor (CaR) from bovine parathyroid provided direct evidence that Ca2+e-sensing can occur through receptor-mediated activation of G proteins and their associated downstream regulators of cellular function. CaR transcripts and protein are present in various tissues of humans and other mammals that are involved in Ca2+e homeostasis, including parathyroid, kidney, and thyroidal C-cells. The present study was performed to determine whether bone marrow cells express the CaR, since cells within the marrow space could be exposed to substantial changes in Ca2+e related to bone turnover. Using DNA and RNA probes from the human parathyroid CaR cDNA, we identified CaR transcripts of 5.2 and ∼4.0 kilobases by Northern analysis of poly(A+) RNA from low-density mononuclear cells isolated from whole human bone marrow that are putatively enriched in marrow progenitor cells, including bone cell precursors. In situ hybridization also identified CaR transcripts in the same cell preparations. Reverse transcription-polymerase chain reaction demonstrated >99% nucleotide identity between transcripts from human bone marrow cells and the corresponding regions of the human CaR cDNA. Antisera specific for several different regions within the extracellular domain of the CaR were reactive with low-density human marrow cells that were either adherent or nonadherent to plastic. About one-third of the adherent, CaR-immunoreactive cells were also positive for alkaline phosphatase, a nonspecific marker of preosteoblasts, osteoblasts, and assorted cells of the colony-forming unit-fibroblast lineage. In addition, a substantial fraction (∼60%) of low density murine marrow cells cultured for 1 week at 4.8 mM Ca2+e expressed both CaR immunoreactivity and nonspecific esterase, an enzyme expressed by monocyte/macrophages and fibroblasts. Finally, erythroid precursors and megakaryocytes from murine marrow as well as blood platelets expressed abundant CaR immunoreactivity, while peripheral blood erythrocytes and most polymorphonuclear leukocytes did not. These studies indicate that the CaR is present in low-density mononuclear bone marrow cells as well as in cells of several hematopoietic lineages and could potentially play a role in controlling the function of various cell types within the marrow space.
- 1 December 1997
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 12 (12) , 1959-1970
Expression of an Extracellular Calcium-Sensing Receptor in Human and Mouse Bone Marrow Cells
The cloning of a G protein–coupled, extracellular calcium (Ca2+e)-sensing receptor (CaR) from bovine parathyroid provided direct evidence that Ca2+e-sensing can occur through receptor-mediated activation of G proteins and their associated downstream regulators of cellular function. CaR transcripts and protein are present in various tissues of humans and other mammals that are involved in Ca2+e homeostasis, including parathyroid, kidney, and thyroidal C-cells. The present study was performed to determine whether bone marrow cells express the CaR, since cells within the marrow space could be exposed to substantial changes in Ca2+e related to bone turnover. Using DNA and RNA probes from the human parathyroid CaR cDNA, we identified CaR transcripts of 5.2 and ∼4.0 kilobases by Northern analysis of poly(A+) RNA from low-density mononuclear cells isolated from whole human bone marrow that are putatively enriched in marrow progenitor cells, including bone cell precursors. In situ hybridization also identified CaR transcripts in the same cell preparations. Reverse transcription-polymerase chain reaction demonstrated >99% nucleotide identity between transcripts from human bone marrow cells and the corresponding regions of the human CaR cDNA. Antisera specific for several different regions within the extracellular domain of the CaR were reactive with low-density human marrow cells that were either adherent or nonadherent to plastic. About one-third of the adherent, CaR-immunoreactive cells were also positive for alkaline phosphatase, a nonspecific marker of preosteoblasts, osteoblasts, and assorted cells of the colony-forming unit-fibroblast lineage. In addition, a substantial fraction (∼60%) of low density murine marrow cells cultured for 1 week at 4.8 mM Ca2+e expressed both CaR immunoreactivity and nonspecific esterase, an enzyme expressed by monocyte/macrophages and fibroblasts. Finally, erythroid precursors and megakaryocytes from murine marrow as well as blood platelets expressed abundant CaR immunoreactivity, while peripheral blood erythrocytes and most polymorphonuclear leukocytes did not. These studies indicate that the CaR is present in low-density mononuclear bone marrow cells as well as in cells of several hematopoietic lineages and could potentially play a role in controlling the function of various cell types within the marrow space.
- 1 August 1997
- Vol. 378 (8) , 759-68
Calcium-sensing receptor: roles in and beyond systemic calcium homeostasis.
The cloning of a Ca2+(0)-sensing receptor (CaR) from parathyroid and kidney, coupled with the identification of inherited disorders in Ca2+(0)-sensing resulting from inactivating or activating mutations of this CaR, has provided substantial insights into how Ca2+(0) is regulated at a systemic level. The CaR plays a central role in mediating, on one hand, the inhibitory effect of Ca2+(0) on parathyroid hormone (PTH) secretion and, on the other, the stimulatory action of Ca2+(0) on calcitonin secretion, which provide for a sophisticated, bi-directional regulation of the secretion of calciotropic hormones mediated by the same receptor. Indeed Ca2+(0) itself can be viewed as a calciotropic 'hormone' acting, along with PTH and calcinotin (CT), on its target tissues involved in mineral ion homeostasis, particularly the kidney. In the kidney, Ca2+zero, acting via the CaR, controls renal handling of divalent mineral ions in the cortical thick ascending limb (CTAL) and perhaps also in the distal convoluted tubule (DCT). In CTAL the CaR not only affects renal calcium handling indirectly by modulating the secretion of PTH but also directly at the level of the tubule, where it is localized on the same basolateal surface of the cells where the PTH receptor is located. Moreover, renal CaRs likely subserve important functions involved in integrating mineral ion metabolism with the homeostasis of water and, perhaps, monovalent cations (e.g., elevating Ca2+(0) produces a CaR-mediated inhibition of NaCl reabsorption in the CTAL). More recent data, however, accumulated since the cloning of the CaR, have suggested additional roles of the receptor in cells uninvolved in mineral ion metabolism. Examples include the brain, intestine and skin, where the receptor may regulate, respectively, the activities of ion channels and probably other neuronal functions, proliferation of the cells of the colonic crypts and differentiation of keratinocytes, presumably in response to local changes in Ca2+(0). It is also possible that the the CaR responds to other endogenous agonists, either polyvalent agonists, such as Mg2+(0) or organic polycations, including spermine or even protamine. Finally additional studies are needed to determine whether there are additional members of a putative family of structurally-related ion-sensing GPCRs, such as that apparently present in osteoblasts that sense Ca2+(0) and, perhaps, in other cell types that recognize additional ions [e.g., Cd2+(0) in dermal fibroblasts (Smith et al., 1989)].
- 1 August 1997
- Vol. 378 (8) , 759-68
Calcium-sensing receptor: roles in and beyond systemic calcium homeostasis.
The cloning of a Ca2+(0)-sensing receptor (CaR) from parathyroid and kidney, coupled with the identification of inherited disorders in Ca2+(0)-sensing resulting from inactivating or activating mutations of this CaR, has provided substantial insights into how Ca2+(0) is regulated at a systemic level. The CaR plays a central role in mediating, on one hand, the inhibitory effect of Ca2+(0) on parathyroid hormone (PTH) secretion and, on the other, the stimulatory action of Ca2+(0) on calcitonin secretion, which provide for a sophisticated, bi-directional regulation of the secretion of calciotropic hormones mediated by the same receptor. Indeed Ca2+(0) itself can be viewed as a calciotropic 'hormone' acting, along with PTH and calcinotin (CT), on its target tissues involved in mineral ion homeostasis, particularly the kidney. In the kidney, Ca2+zero, acting via the CaR, controls renal handling of divalent mineral ions in the cortical thick ascending limb (CTAL) and perhaps also in the distal convoluted tubule (DCT). In CTAL the CaR not only affects renal calcium handling indirectly by modulating the secretion of PTH but also directly at the level of the tubule, where it is localized on the same basolateal surface of the cells where the PTH receptor is located. Moreover, renal CaRs likely subserve important functions involved in integrating mineral ion metabolism with the homeostasis of water and, perhaps, monovalent cations (e.g., elevating Ca2+(0) produces a CaR-mediated inhibition of NaCl reabsorption in the CTAL). More recent data, however, accumulated since the cloning of the CaR, have suggested additional roles of the receptor in cells uninvolved in mineral ion metabolism. Examples include the brain, intestine and skin, where the receptor may regulate, respectively, the activities of ion channels and probably other neuronal functions, proliferation of the cells of the colonic crypts and differentiation of keratinocytes, presumably in response to local changes in Ca2+(0). It is also possible that the the CaR responds to other endogenous agonists, either polyvalent agonists, such as Mg2+(0) or organic polycations, including spermine or even protamine. Finally additional studies are needed to determine whether there are additional members of a putative family of structurally-related ion-sensing GPCRs, such as that apparently present in osteoblasts that sense Ca2+(0) and, perhaps, in other cell types that recognize additional ions [e.g., Cd2+(0) in dermal fibroblasts (Smith et al., 1989)].
- 1 April 1997
- Published by Springer Nature in Pediatric Research
- Vol. 41 (4) , 277
Hypercalcemia Selectively Decreases Rat Inner Medullary Collecting Duct(IMCD) Vasopressin (AVP)-Elicited Water Permeability (Pf) and Aquaporin-2 (AQP-2) Water Channel Protein Content While Increasing Its Urea Permeability (Purea) and the UT-2 Urea Channel Protein Content • 1650
- 1 April 1997
- Published by Springer Nature in Pediatric Research
- Vol. 41 (4) , 277
Hypercalcemia Selectively Decreases Rat Inner Medullary Collecting Duct(IMCD) Vasopressin (AVP)-Elicited Water Permeability (Pf) and Aquaporin-2 (AQP-2) Water Channel Protein Content While Increasing Its Urea Permeability (Purea) and the UT-2 Urea Channel Protein Content • 1650
- 1 January 1997
- Published by S. Karger AG in Hormone Research
- Vol. 48 (5) , 199-208
Mutations in the Calcium-Sensing Receptor and Their Clinical Implications
Specialized cells (i.e., parathyroid chief cells) that sense changes in the extracellular calcium concentration are a key element in mineral ion homeostasis. The Ca2+o-sensing receptor (CaR) originally cloned from bovine parathyroid is also present in multiple nephron segments involved in Ca2+o homeostasis as well as in other sites that are not, such as brain, lung, large and small intestine. The physiological relevance of the CaR has been established by identifying hyper- and hypocalcemic disorders resulting from CaR mutations: familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism result from inactivating CaR mutations, while an autosomal dominant form of hypocalcemia is caused by activating mutations. In addition to sensing Ca2+o and Mg2+o abnormally (the latter suggesting the CaR acts as an Mg2+o-sensing receptor), persons with FHH have alterations in their handling of water, supporting a role for the CaR in integrating mineral ion and water metabolism. Drugs that activate the CaR (‘calcimimetics’) are currently undergoing clinical trials and will permit pharmacological manipulation of the receptor when it functions abnormally (e.g., in primary hyperparathyroidism).
- 1 January 1997
- Published by S. Karger AG in Hormone Research
- Vol. 48 (5) , 199-208
Mutations in the Calcium-Sensing Receptor and Their Clinical Implications
Specialized cells (i.e., parathyroid chief cells) that sense changes in the extracellular calcium concentration are a key element in mineral ion homeostasis. The Ca2+o-sensing receptor (CaR) originally cloned from bovine parathyroid is also present in multiple nephron segments involved in Ca2+o homeostasis as well as in other sites that are not, such as brain, lung, large and small intestine. The physiological relevance of the CaR has been established by identifying hyper- and hypocalcemic disorders resulting from CaR mutations: familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism result from inactivating CaR mutations, while an autosomal dominant form of hypocalcemia is caused by activating mutations. In addition to sensing Ca2+o and Mg2+o abnormally (the latter suggesting the CaR acts as an Mg2+o-sensing receptor), persons with FHH have alterations in their handling of water, supporting a role for the CaR in integrating mineral ion and water metabolism. Drugs that activate the CaR (‘calcimimetics’) are currently undergoing clinical trials and will permit pharmacological manipulation of the receptor when it functions abnormally (e.g., in primary hyperparathyroidism).
- 1 September 1996
- Vol. 312 (3) , 99-109
The First Annual Bayard D. Catherwood Memorial Lecture. Ca2+-receptor-mediated regulation of parathyroid and renal function.
The recent cloning of an extracellular calcium (Ca2+o)-sensing receptor (CaR) from the parathyroid gland and the kidney has provided novel insights into the mechanisms that underlie the direct actions of Ca2+o on various cells. The receptor is a member of the superfamily of G protein-coupled receptors, activating phospholipase C (PLC) and probably also inhibiting adenylate cyclase in target tissues. In the parathyroid gland it is a key mediator of the inhibition by high Ca2+o of parathyroid hormone (PTH) secretion and, perhaps, PTH gene expression and parathyroid cellular proliferation. It also appears to represent the major mechanism through which Ca2+o stimulates the secretion of calcitonin from the thyroidal C-cells. In the kidney, the CaR directly inhibits tubular reabsorption of calcium and magnesium in the thick ascending limb, and may be responsible for the long-recognized, but poorly understood inhibition of urinary concentrating ability by hypercalcemia. The demonstration that activating and inactivating mutations of the CaR, respectively, are the proximate causes of the inherited hypocalcemic disorder, autosomal dominant hypocalcemia (ADH) and the hypercalcemic diseases, familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT), has provided additional strong support for the physiologic importance of the CaR in human mineral ion homeostasis. Therefore, when Ca2+o acts through its own G protein-coupled cell surface receptor, it acts as an extracellular first messenger in addition to serving its better recognized role as a key intracellular second messenger.
- 1 September 1996
- Vol. 312 (3) , 99-109
The First Annual Bayard D. Catherwood Memorial Lecture. Ca2+-receptor-mediated regulation of parathyroid and renal function.
The recent cloning of an extracellular calcium (Ca2+o)-sensing receptor (CaR) from the parathyroid gland and the kidney has provided novel insights into the mechanisms that underlie the direct actions of Ca2+o on various cells. The receptor is a member of the superfamily of G protein-coupled receptors, activating phospholipase C (PLC) and probably also inhibiting adenylate cyclase in target tissues. In the parathyroid gland it is a key mediator of the inhibition by high Ca2+o of parathyroid hormone (PTH) secretion and, perhaps, PTH gene expression and parathyroid cellular proliferation. It also appears to represent the major mechanism through which Ca2+o stimulates the secretion of calcitonin from the thyroidal C-cells. In the kidney, the CaR directly inhibits tubular reabsorption of calcium and magnesium in the thick ascending limb, and may be responsible for the long-recognized, but poorly understood inhibition of urinary concentrating ability by hypercalcemia. The demonstration that activating and inactivating mutations of the CaR, respectively, are the proximate causes of the inherited hypocalcemic disorder, autosomal dominant hypocalcemia (ADH) and the hypercalcemic diseases, familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT), has provided additional strong support for the physiologic importance of the CaR in human mineral ion homeostasis. Therefore, when Ca2+o acts through its own G protein-coupled cell surface receptor, it acts as an extracellular first messenger in addition to serving its better recognized role as a key intracellular second messenger.